TLSA
Company Description
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (18.43M) | (11.86M) | (22.36M) | (18.92M) | (31.59M) | (35.54M) | (9.36M) | (7.98M) | (6.77M) | (7.21M) | (8.63M) | (3.51M) |
| EPS | -0.32 | -0.22 | -0.42 | -0.36 | -0.64 | -0.74 | -0.14 | -0.12 | -0.12 | -0.14 | -0.18 | -0.62 |
| Free Cash Flow | (12.87M) | (1.23M) | (12.42M) | (15.99M) | (16.15M) | (8.76M) | (5.29M) | (4.60M) | (5.68M) | (5.65M) | (5.70M) | (2.31M) |
| FCF / Share | -0.22 | -0.02 | -0.24 | -0.31 | -0.33 | -0.18 | -0.08 | -0.07 | -0.10 | -0.11 | -0.12 | -0.40 |
| Operating CF | (12.85M) | (1.22M) | (12.42M) | (15.99M) | (16.13M) | (8.76M) | (5.29M) | (4.60M) | (5.68M) | (5.62M) | (5.70M) | (2.31M) |
| Total Assets | 11.49M | 11.28M | 12.18M | 26.48M | 48.83M | 70.66M | 1.81M | 6.91M | 1.83M | 5.05M | 9.25M | 2.46M |
| Total Debt | 456,000 | 106,000 | 247,000 | 365,000 | 1.35M | 555,000 | 1.42M | 309,463 | 234,000 | 225,000 | 216,000 | 206,000 |
| Cash & Equiv | 4.01M | 3.72M | 1.18M | 18.12M | 42.19M | 65.82M | 153,000 | 5.29M | 48,000 | 4.70M | 8.90M | 2.27M |
| Book Value | 52,000 | 3.94M | 5.54M | 19.57M | 41.28M | 45.71M | (4.18M) | 518,103 | (1.68M) | 3.31M | 8.50M | 1.78M |
| Return on Equity | -354.44 | -3.01 | -4.04 | -0.97 | -0.77 | -0.78 | N/A | -15.40 | N/A | -2.18 | -1.02 | -1.98 |
| Metric | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 | Q4 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.80M) | (5.63M) | (7.21M) | (9.31M) | (9.07M) | (10.91M) | (13.38M) | (5.48M) | (3.21M) | (17.48M) | (21.43M) | (4.95M) |
| EPS | -0.22 | -0.10 | -0.13 | -0.18 | -0.18 | -0.20 | -0.28 | -0.10 | -28.90 | -0.24 | -0.24 | -0.07 |
| Free Cash Flow | (6.04M) | (6.83M) | (1.54M) | 304,943 | (3.41M) | (8.99M) | (6.28M) | (9.81M) | (4.58M) | (13.07M) | (5.76M) | (6.38M) |
| FCF / Share | -0.10 | -0.12 | -0.03 | 0.01 | -0.07 | -0.18 | -0.12 | -0.19 | -0.04 | -0.17 | -0.13 | -0.08 |
| Operating CF | (6.02M) | (6.82M) | (1.54M) | 316,004 | (3.41M) | (8.99M) | (6.28M) | (9.81M) | (4.58M) | (13.05M) | (5.76M) | (6.38M) |
| Total Assets | 11.49M | 16.60M | 11.28M | 10.96M | 12.18M | 17.42M | 26.48M | 35.03M | N/A | 57.94M | N/A | 13.08M |
| Total Debt | 456,000 | 107,000 | 106,000 | 179,000 | 247,000 | 353,000 | 365,000 | 0 | N/A | 1.15M | N/A | 1.10M |
| Cash & Equiv | 4.01M | 7.25M | 3.72M | 1.13M | 1.18M | 6.60M | 18.12M | 26.47M | N/A | 53.34M | N/A | 8.97M |
| Book Value | 52,000 | 9.20M | 3.94M | 1.85M | 5.54M | 13.29M | 19.57M | 29.76M | N/A | 48.76M | N/A | 6.16M |
| Return on Equity | -246.13 | -0.61 | -1.83 | -5.02 | -1.64 | -0.82 | -0.68 | -0.18 | N/A | -0.36 | N/A | -0.80 |
